Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T31133
(Former ID: TTDI01287)
|
|||||
| Target Name |
Potassium (K)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Hyperkalaemia [ICD-11: 5C76] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 2 Approved Drugs | + | ||||
| 1 | Patiromer calcium | Drug Info | Approved | Hyperkalemia | [2] | |
| 2 | Sodium zirconium cyclosilicate | Drug Info | Approved | Hyperkalemia | [3] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Binder | [+] 2 Binder drugs | + | ||||
| 1 | Patiromer calcium | Drug Info | [1] | |||
| 2 | Sodium zirconium cyclosilicate | Drug Info | [3] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011 Apr;32(7):820-8. | |||||
| REF 2 | ClinicalTrials.gov (NCT01810939) A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia. U.S. National Institutes of Health. | |||||
| REF 3 | 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.